Our Sponsors
Website https://www.virtueinsight.com/pharma/4th-Pharma-Pricing-Reimbursement--Market-Access-2021-Virtual-Co |
Edit Freely
Category PHARMA
Deadline: June 27, 2021 | Date: June 28, 2021-June 29, 2021
Venue/Country: Online Conference, U.K.
Updated: 2021-06-07 16:27:50 (GMT+9)
virtueinsight.co.in or Call: +44-20 3509 3779Please note that this is a PAID event and NOT A FREE event (no complimentary passes available). Any invite, email or tickets issued mentioning it as a free pass or free ticket to this event through any third party site will strictly not be accepted by the organizer. EARLY BIRD PRICE1 Delegate
£300 +VAT (Valid Till 24th May 2021)3 Delegates
£700 +VAT (Valid Till 24th May 2021)STANDARD PRICE1 Delegate
£500 +VAT (Valid From 25th May 2021)3 Delegates
£1200 +VAT (Valid From 25th May 2021)Conference Sponsor, Exhibition Stall & Paid Speaker Slot - Please email your interest and queries to kavitha
virtueinsight.co.in KEY SPEAKERS:• GERGANA ZLATEVA, Vice President and Business Unit Lead, Oncology, Patient & Health Impact, Pfizer• VIVECA PARKER, Assistant US Attorney, Dept of Justice• ADAM LEVYSOHN, Head of Biogen Value & Access Alzheimer’s Disease, Biogen• MARIA ALEJANDRA BLANC, Director - Regulatory Affairs, Abbvie• MARIO OUWENS, Senior Statistical Science Director, Group director Medical & Payer Evidence Statistics, AstraZeneca• LAURENE REDDING, Head, Value, Access & Policy, BeiGene• LARA PIPPO, Head of Market Access & Government Affairs, CSL Behring• SAMUEL MURPHY, VP & Head of International BD, Shenzhen Salubris Pharmaceuticals• VIJAY REDDY, Senior Director - Global Market Access Strategy, Biocon Biologics• ALEEN HOSDAGHIAN, Brand Lead, US Immunology, UCB Pharma• JESPER BJERGGREN, European Market Access Lead, Digital Health, Teva Pharmaceuticals• OMAR ALI, Pharmacist Consultant, QIPP Adviser Payer Network• SARAH GARNER, Acting Program Manager - Access to Medicines and Health Products, WHO• MARCO MARCHETTI, Director, National Center for HTA, Istituto Superiore di Sanità• MARTIN SCHUCHARDT, Global Market Access & Pricing Lead, Almirall• NURIYA MUSINA, Head of Development, Center of Healthcare Quality Assessment and Control, Ministry of Health of The RF• ROBERT POPOVIAN, CEO, Former VP, Gov Relations, Conquest Advisors, Pfizer• LUC BOILEAU, President - Director General, INESSS• ISABELLE GANACHE, Director, INESSS• OLIVER LEATHAM, VP, Global Head of Commercial Strategy and EU Value & Access, Certara• MARTIJN NEGEN, VP Commercial Strategy, AM Pharma• IGOR RUDYCHEV, Vice President, Enterprise Analytics, Horizon Therapeutics• ROSEMARY JOSE, Senior Director, Strategic Market Access, Open Health• JUAN VERGEZ, Head of Marketing & Corporate Communications, Arvelle Therapeutics• ERIN MISTRY, SVP Payer Strategy, Government Affairs and Trade, Cormedix• REED STEPHENS, Partner, Winston & Strawn• TIM EPPLE, Principal, Financial Services, Avalere Health• ALEXANDER NATZ, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)• MICHAEL THOMPSON, President & CEO, National Alliance of Healthcare Purchaser Coalition• SANDY EISEN, Chief Medical Officer, Frontline Pharma Consulting LtdPlus more joining soonKEY THEMES DISCUSSED IN THIS CONFERENCE: • Preparing your best market access strategy• EU and US policy challenges for market access: Stepping ahead• Unrivalled opportunity to expose and address the market access challenges facing the industry• Current & future - Challenges & opportunities in pharma pricing, reimbursement & market access• Improving patient and market access through the development of targeted value propositions, comprehensive contract assessment• Measurement strategies through to in-depth knowledge regarding payer formulary coverage trends• How can payers and industry work together to ensure that innovative and valuable treatments make it to the market?• Understanding - payers’ perspective• Advocating and collaborating with payers for value in a new era• Creating a robust patient services and reimbursement support program for biosimilar products• Prioritising Patients! - Adding value through an innovative patient-centered approach• Understand how price affects market access and learn on how to set prices for optimal access and returns.• New drugs are failing to gain reimbursement from payers/HTAs at an alarming rate, despite being approved by regulators• Evidence Generation - The strategic rigor and creativity applied to evidence generation• Impact of social media and digital analytics• Developing risk-sharing reimbursement models and value based pricing• Patient engagement and adherence within the environment• Explaining how to use the data sources and observational research for effective safety analysis• Dwell ahead of regulatory developments & improving your strategies in a cost effective way in EU, US• Accelerating new medicine introduction in developing world & overcoming challenges• Be part of a major networking opportunityWHO SHOULD ATTEND: Senior Vice Presidents, Vice Presidents, Senior Executives, Global Heads, Heads, Directors, Senior Managers, Managers of:Pricing, Reimbursement, Market Access, Commercial Pricing, Pricing Strategists, Health Economics, Outcomes Research, Regulatory Affairs, Governmental Affairs, Public Affairs, Public Policy Directors, Operations, Governmental bodies, Regulatory bodiesGet more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking time, meet the leading international vendors showcasing the products of tomorrow in the virtual exhibition area. Expand your knowledge of the latest business models and strategies in the high-level conference.Keywords: Accepted papers list. Acceptance Rate. EI Compendex. Engineering Index. ISTP index. ISI index. Impact Factor.
Disclaimer: ourGlocal is an open academical resource system, which anyone can edit or update. Usually, journal information updated by us, journal managers or others. So the information is old or wrong now. Specially, impact factor is changing every year. Even it was correct when updated, it may have been changed now. So please go to Thomson Reuters to confirm latest value about Journal impact factor.